MARKET

CERS

CERS

Cerus Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.79
+0.01
+0.09%
Opening 13:33 05/11 EDT
OPEN
5.55
PREV CLOSE
5.78
HIGH
5.79
LOW
5.55
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
5.05
MARKET CAP
990.23M
P/E (TTM)
-15.8624
1D
5D
1M
3M
1Y
5Y
DJ Cerus Corporation CEO Obi Greenman on Q1 2021 Results -- Earnings Call Transcript >CERS
Dow Jones · 6d ago
Pathogen Reduction System Market Size, Share, Trends, Analysis and Forecast 2027
May 05, 2021 (Market Insight Reports) -- The Global Pathogen Reduction System Market is estimated to value over USD 5.2 billion by 2027 end at a CAGR of over...
Market Insight Reports · 6d ago
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of -11.11% and 8.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
10-Q: CERUS CORP
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis...
Edgar Online - (EDG = 10Q, 10K) · 6d ago
BRIEF-Cerus Corp Announces Q1 2021 Financial Results And Raises Full Year Product Revenue Guidance
reuters.com · 6d ago
Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance
Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2021.
Business Wire · 6d ago
Cerus EPS in-line, beats on revenue
Cerus (CERS): Q1 GAAP EPS of -$0.10 in-line.Revenue of $23.38M (+25.6% Y/Y) beats by $1.31M.Cash, cash equivalents, and short-term investments of $132 million at March 31, 2021.Raised guidance: The Company now
Seekingalpha · 6d ago
Cerus Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $29.60M Beat $28.18M Estimate
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is unchanged from the same period last year. The company reported
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERS. Analyze the recent business situations of Cerus Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERS stock price target is 9.10 with a high estimate of 10.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 238
Institutional Holdings: 154.03M
% Owned: 89.99%
Shares Outstanding: 171.17M
TypeInstitutionsShares
Increased
55
6.34M
New
25
4.13M
Decreased
51
5.90M
Sold Out
22
822.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.37%
Healthcare Equipment & Supplies
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
General Counsel
Chrystal Menard
Other
Richard Benjamin
Independent Director
Timothy Anderson
Independent Director
Eric Bjerkholt
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
Independent Director
Franklin Witney
No Data
About CERS
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.